Apply to trial NCT06169371

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 4Drug trial

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening